ClinicalTrials.gg
RecruitingNCT07684339PLCZetaUpdated Nov 12, 2026

Assessing the Correlation Between Phospholipase C Zeta Measurements and Semen Parameters

An observational study in Male Infertility and Male Subfertility, sponsored by Fakih IVF Fertility Center. Recruiting at 2 sites in United Arab Emirates. Open to male participants. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Fakih IVF Fertility Center · Observational

How we know

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.
Updated Nov 12, 2026Site recruiting status changedStart date moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
200
Sex
Male
01

Study summary

With declining fertility rates Worldwide, Assisted Reproductive Technology is seen as a viable solution for infertility, however, individual success rates following ART remain relatively low, rarely exceeding \~50%. The European Society for Human Reproduction and Embryology (ESHRE) indicates pregnancy rates per embryo transfer remain below 50%. Additionally, male infertility is regarded as a leading contributor to global infertility with approximately a third of cases attributed to genetic causes while half of the cases remain unexplained.

In this observational study we investigate the correlation between phospholipase C Zeta (PLCζ ) measurements and semen parameters. PLCζ is a sperm-specific protein which is introduced into a mature egg (oocyte) following gamete fusion and upon introduction, PLCζ is believed to initiate a series of characteristic calcium ion oscillations which lead to oocyte activation and persist beyond the completion of meiosis.

Mounting evidence implicates defects in PLCζ in cases of male factor infertility where intracytoplasmic sperm injection (ICSI; whereby a single sperm is injected into the oocyte) is unsuccessful. Furthermore, defects in PLCζ are also increasingly implicated in cases of male sub-fertility, which affects a much larger proportion of the global population. Numerous studies now indicate that PLCζ not only holds significant value as a therapeutic to rescue cases of ICSI failure, but also as a prognostic diagnostic test of male fertility. Indeed, the reduction or absence of normal PLCζ within sperm has been linked to cases of male factor infertility in humans, either due to inactivation through mutation, due to abrogation of protein levels in sperm as a result of mutation in the PLCζ promoter, or mutations within coding exonic regions of the PLCζ gene. Such data indicate both therapeutic, and diagnostic applications for PLCζ within the fertility clinic. This study seeks to determine the effect of abnormal PLCζ on semen parameters and correlate that with downstream events including clinical pregnancy and live birth rates.

Read the detailed description

Despite advances in assisted reproductive technology (ART), significant gaps remain in understanding recurrent implantation failure and abortive embryogenesis. Male factor infertility is globally the leading cause of infertility, and is particularly prevalent in GCC countries, notably the UAE; where fertility rates have halved over the past decade, driven by cultural, lifestyle, and environmental shifts. Poor semen parameters (sperm count, motility, and morphology) account for 41% of infertility cases in the region.

The financial burden is substantial: a single ART cycle can exceed AED 30,000, with couples typically requiring 2-3 cycles (AED 60,000-100,000), translating to an estimated national expenditure of \~AED 0.5 billion annually in fertility treatments alone, excluding associated healthcare investigations.

A critical and underexplored mechanism underlying poor ART outcomes involves oocyte activation, initiated at fertilization by characteristic intracellular calcium (Ca²⁺) oscillations. These are triggered by phospholipase C zeta (PLCζ), a sperm-specific protein delivered into the oocyte upon gamete fusion. Ca²⁺ oscillation profiles directly govern cell cycle progression, embryo gene expression, and early developmental competence; deviations in amplitude or frequency compromise embryo quality. Notably, preimplantation mouse studies show that both insufficient and excessive PLCζ impair blastocyst development, with successful outcomes occurring within a \~4-fold effective dose range - mirroring the natural variation of PLCζ levels observed across fertile men.

Mounting clinical evidence links reduced or absent sperm PLCζ to fertilization failure following intracytoplasmic sperm injection (ICSI), as well as to broader male sub-fertility. PLCζ deficiencies may arise through point mutations, promoter alterations, or disrupted exonic regions, and correlate with known sperm defects including poor motility, globozoospermia, and elevated DNA fragmentation. Crucially, even when residual PLCζ is sufficient to trigger oocyte activation, it may be inadequate for full embryonic competence, a distinction with major clinical implications for sub-fertile men.

Despite this evidence, the direct relationship between sperm PLCζ parameters and downstream outcomes including embryonic efficacy, recurrent implantation failure, and ART success rates has not yet been systematically investigated. We propose that abnormalities in PLCζ-mediated Ca²⁺ oscillations represent a significant and underappreciated contributor to poor global ART outcomes. Establishing this link would position PLCζ as both a prognostic diagnostic marker of sperm health and a therapeutic agent, with the potential to improve outcomes across a broad spectrum of infertility presentations beyond complete fertilization failure.

02

Conditions studied

  • Male Infertility
  • Male Subfertility

Browse trials for

Keywords

  • PLCζ
  • phospholipase C Zeta
  • Male Infertility
03

In context

Infertility, Male

283 studies on the registry are indexed under Infertility, Male; 65 are open to participants now.

This study's planned enrollment of 200 is close to the median of 182 across 87 observational studies indexed under Infertility, Male.

Browse Infertility, Male studies →

Lead sponsor

Fakih IVF Fertility Center is the lead sponsor of 6 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Male
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Male partners in couples suffering from infertility and seeking IVF treatment at the FAKIH IVF clinics in the UAE.

Eligibility criteria

Couple inclusion criteria:

  • Presenting to the IVF clinic for IVF/ICSI treatment or routine semen analysis
  • Semen sample must have a total sperm count of ≥1 million sperm/ml
  • Availability of excess, leftover sperm after clinical treatment procedures
  • Couples must have experienced infertility for at least one year and be undergoing fertility treatment
  • Undergoing standard clinical treatment protocols (including embryo culture and, when applicable, PGTA) with routinely collected treatment outcome data
  • Sufficient ovarian reserve and/or meeting the clinic's standard criteria for fertility treatment

Couple exclusion criteria:

  • Known genetic disorders affecting fertility
  • History of vasectomy or other irreversible sterilization procedures
  • Current use of medications known to affect sperm parameters (e.g., exogenous androgens, chemotherapeutic agents, or other drugs specifically impacting spermatogenesis)
  • Recent history of chemotherapy or radiation therapy
  • Female age >38 years old
  • Known chromosomal abnormalities or genetic disorders that directly affect oocyte quality or embryo development
  • Presence of severe uterine or pelvic pathology (e.g., significant uterine anomalies, advanced endometriosis)
  • Documented ovarian failure or extremely diminished ovarian reserve as determined by AMH levels (AMH >1 ng/mL, AFC ≥5)
  • Use of medications or undergoing treatments that could significantly alter oocyte quality or embryogenesis (outside standard ART protocols).
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
200 participants (estimated)
Patient registry
No

Groups and cohorts

  • IVF-couples

    Male partners in couples seeking fertility treatment via IVF and excluding any couples with factors known to negatively affect in spermatogenesis and embryogenesis. Couples must be experiencing infertility for 1 year or more before beginning IVF treatment.

    Other: No Intervention: Observational Cohort

Interventions

  • OtherNo Intervention: Observational Cohort

    This is a cohort observational study and there will be no intervention of any type.

06

What researchers measure

Primary outcomes

  1. Biochemical pregnancy

    Blood tested positive/ negative for pregnancy

    Time frame: From enrollment to clinical pregnancy result and delivery where applicable.

  2. Clinical Pregnancy result

    Confirmation of presence or absence of a gestational sac and fetal heartbeat using ultrasound detection.

    Time frame: From enrollment to delivery (live birth or miscarriage)

  3. PLC Zeta measurement

    Measurement of PLC Zeta by Immunofluorescence and Western Blotting

    Time frame: From enrollment to submission of sperm (1 day)

Secondary outcomes

  1. Live birth or miscarriage

    Live birth rates/ Miscarriage rates

    Time frame: From enrollment to delivery or miscarriage.

07

Study locations

2 of 2 sites recruiting
  • Fakih IVF
    Abu Dhabi, United Arab Emirates
    Recruiting
  • Khalifa University
    Abu Dhabi, United Arab Emirates
    Recruiting
08

References and documents

Publications

  • World Health Organization, 2010, Fifth Edition. ISBN: 978 92 4 154778 9.
  • Yamaguchi et al., Cell Calcium 2017;pii: S0143-4160(16)30191-9.
  • Janghorban-Laricheh E, Ghazavi-Khorasgani N, Tavalaee M, Zohrabi D, Abbasi H, Nasr-Esfahani MH. An association between sperm PLCzeta levels and varicocele? J Assist Reprod Genet. 2016 Dec;33(12):1649-1655. doi: 10.1007/s10815-016-0802-5. Epub 2016 Sep 9. PubMed 27612872 ↗
  • Kamali-Dolat Abadi M, Tavalaee M, Shahverdi A, Nasr-Esfahani MH. Evaluation of PLCzeta and PAWP Expression in Globozoospermic Individuals. Cell J. 2016 Fall;18(3):438-45. doi: 10.22074/cellj.2016.4572. Epub 2016 Aug 24. PubMed 27602326 ↗
  • Wong CC, Loewke KE, Bossert NL, Behr B, De Jonge CJ, Baer TM, Reijo Pera RA. Non-invasive imaging of human embryos before embryonic genome activation predicts development to the blastocyst stage. Nat Biotechnol. 2010 Oct;28(10):1115-21. doi: 10.1038/nbt.1686. Epub 2010 Oct 3. PubMed 20890283 ↗
  • Miyazaki S, Ito M. Calcium signals for egg activation in mammals. J Pharmacol Sci. 2006;100(5):545-52. doi: 10.1254/jphs.cpj06003x. PubMed 16799264 ↗
  • Fulton BP, Whittingham DG. Activation of mammalian oocytes by intracellular injection of calcium. Nature. 1978 May 11;273(5658):149-51. doi: 10.1038/273149a0. No abstract available. PubMed 565475 ↗
  • Ducibella T, Schultz RM, Ozil JP. Role of calcium signals in early development. Semin Cell Dev Biol. 2006 Apr;17(2):324-32. doi: 10.1016/j.semcdb.2006.02.010. Epub 2006 Mar 2. PubMed 16580237 ↗
  • Ducibella T, Huneau D, Angelichio E, Xu Z, Schultz RM, Kopf GS, Fissore R, Madoux S, Ozil JP. Egg-to-embryo transition is driven by differential responses to Ca(2+) oscillation number. Dev Biol. 2002 Oct 15;250(2):280-91. PubMed 12376103 ↗
  • Escoffier J, Lee HC, Yassine S, Zouari R, Martinez G, Karaouzene T, Coutton C, Kherraf ZE, Halouani L, Triki C, Nef S, Thierry-Mieg N, Savinov SN, Fissore R, Ray PF, Arnoult C. Homozygous mutation of PLCZ1 leads to defective human oocyte activation and infertility that is not rescued by the WW-binding protein PAWP. Hum Mol Genet. 2016 Mar 1;25(5):878-91. doi: 10.1093/hmg/ddv617. Epub 2015 Dec 31. PubMed 26721930 ↗
  • Ferrer-Vaquer A, Barragan M, Freour T, Vernaeve V, Vassena R. PLCzeta sequence, protein levels, and distribution in human sperm do not correlate with semen characteristics and fertilization rates after ICSI. J Assist Reprod Genet. 2016 Jun;33(6):747-56. doi: 10.1007/s10815-016-0718-0. Epub 2016 May 2. PubMed 27138933 ↗
  • Kashir J, Konstantinidis M, Jones C, Heindryckx B, De Sutter P, Parrington J, Wells D, Coward K. Characterization of two heterozygous mutations of the oocyte activation factor phospholipase C zeta (PLCzeta) from an infertile man by use of minisequencing of individual sperm and expression in somatic cells. Fertil Steril. 2012 Aug;98(2):423-31. doi: 10.1016/j.fertnstert.2012.05.002. Epub 2012 May 24. PubMed 22633260 ↗
  • Kashir J, Konstantinidis M, Jones C, Lemmon B, Lee HC, Hamer R, Heindryckx B, Deane CM, De Sutter P, Fissore RA, Parrington J, Wells D, Coward K. A maternally inherited autosomal point mutation in human phospholipase C zeta (PLCzeta) leads to male infertility. Hum Reprod. 2012 Jan;27(1):222-31. doi: 10.1093/humrep/der384. Epub 2011 Nov 16. PubMed 22095789 ↗
  • Kashir J, Buntwal L, Nomikos M, Calver BL, Stamatiadis P, Ashley P, Vassilakopoulou V, Sanders D, Knaggs P, Livaniou E, Bunkheila A, Swann K, Lai FA. Antigen unmasking enhances visualization efficacy of the oocyte activation factor, phospholipase C zeta, in mammalian sperm. Mol Hum Reprod. 2017 Jan;23(1):54-67. doi: 10.1093/molehr/gaw073. Epub 2016 Dec 8. PubMed 27932551 ↗
  • Theodoridou M, Nomikos M, Parthimos D, Gonzalez-Garcia JR, Elgmati K, Calver BL, Sideratou Z, Nounesis G, Swann K, Lai FA. Chimeras of sperm PLCzeta reveal disparate protein domain functions in the generation of intracellular Ca2+ oscillations in mammalian eggs at fertilization. Mol Hum Reprod. 2013 Dec;19(12):852-64. doi: 10.1093/molehr/gat070. Epub 2013 Oct 23. PubMed 24152875 ↗
  • Kashir J, Nomikos M, Lai FA, Swann K. Sperm-induced Ca2+ release during egg activation in mammals. Biochem Biophys Res Commun. 2014 Aug 1;450(3):1204-11. doi: 10.1016/j.bbrc.2014.04.078. Epub 2014 Apr 21. PubMed 24769204 ↗
  • Kashir J, Heynen A, Jones C, Durrans C, Craig J, Gadea J, Turner K, Parrington J, Coward K. Effects of cryopreservation and density-gradient washing on phospholipase C zeta concentrations in human spermatozoa. Reprod Biomed Online. 2011 Aug;23(2):263-7. doi: 10.1016/j.rbmo.2011.04.006. Epub 2011 May 7. PubMed 21665540 ↗
  • Kashir J, Jones C, Lee HC, Rietdorf K, Nikiforaki D, Durrans C, Ruas M, Tee ST, Heindryckx B, Galione A, De Sutter P, Fissore RA, Parrington J, Coward K. Loss of activity mutations in phospholipase C zeta (PLCzeta) abolishes calcium oscillatory ability of human recombinant protein in mouse oocytes. Hum Reprod. 2011 Dec;26(12):3372-87. doi: 10.1093/humrep/der336. Epub 2011 Oct 18. PubMed 22010140 ↗
  • Yoon SY, Jellerette T, Salicioni AM, Lee HC, Yoo MS, Coward K, Parrington J, Grow D, Cibelli JB, Visconti PE, Mager J, Fissore RA. Human sperm devoid of PLC, zeta 1 fail to induce Ca(2+) release and are unable to initiate the first step of embryo development. J Clin Invest. 2008 Nov;118(11):3671-81. doi: 10.1172/JCI36942. Epub 2008 Oct 16. PubMed 18924610 ↗
  • Saunders CM, Larman MG, Parrington J, Cox LJ, Royse J, Blayney LM, Swann K, Lai FA. PLC zeta: a sperm-specific trigger of Ca(2+) oscillations in eggs and embryo development. Development. 2002 Aug;129(15):3533-44. doi: 10.1242/dev.129.15.3533. PubMed 12117804 ↗
  • Ito J, Parrington J, Fissore RA. PLCzeta and its role as a trigger of development in vertebrates. Mol Reprod Dev. 2011 Oct-Nov;78(10-11):846-53. doi: 10.1002/mrd.21359. Epub 2011 Aug 5. PubMed 21823187 ↗
  • Swann K, Yu Y. The dynamics of calcium oscillations that activate mammalian eggs. Int J Dev Biol. 2008;52(5-6):585-94. doi: 10.1387/ijdb.072530ks. PubMed 18649272 ↗
  • Publicover S, Harper CV, Barratt C. [Ca2+]i signalling in sperm--making the most of what you've got. Nat Cell Biol. 2007 Mar;9(3):235-42. doi: 10.1038/ncb0307-235. PubMed 17330112 ↗
  • Swann K, Ozil JP. Dynamics of the calcium signal that triggers mammalian egg activation. Int Rev Cytol. 1994;152:183-222. doi: 10.1016/s0074-7696(08)62557-7. No abstract available. PubMed 8206704 ↗
  • Kline D, Kline JT. Repetitive calcium transients and the role of calcium in exocytosis and cell cycle activation in the mouse egg. Dev Biol. 1992 Jan;149(1):80-9. doi: 10.1016/0012-1606(92)90265-i. PubMed 1728596 ↗
  • Alshahrani S, Ahmed AF, Gabr AH, Abalhassan M, Ahmad G. The impact of body mass index on semen parameters in infertile men. Andrologia. 2016 Dec;48(10):1125-1129. doi: 10.1111/and.12549. Epub 2016 Feb 5. PubMed 26847036 ↗
  • Al-Turki HA. A 5-year analysis of semen parameters in Saudi Arabian men attending infertility clinics. J Int Med Res. 2016 Jun;44(3):656-61. doi: 10.1177/0300060516632108. Epub 2016 Apr 1. PubMed 27036147 ↗
  • Harton GL, Tempest HG. Chromosomal disorders and male infertility. Asian J Androl. 2012 Jan;14(1):32-9. doi: 10.1038/aja.2011.66. Epub 2011 Nov 28. PubMed 22120929 ↗
  • Hotaling JM. Genetics of male infertility. Urol Clin North Am. 2014 Feb;41(1):1-17. doi: 10.1016/j.ucl.2013.08.009. Epub 2013 Oct 23. PubMed 24286764 ↗
  • Gunes S, Arslan MA, Hekim GNT, Asci R. The role of epigenetics in idiopathic male infertility. J Assist Reprod Genet. 2016 May;33(5):553-569. doi: 10.1007/s10815-016-0682-8. Epub 2016 Mar 3. PubMed 26941097 ↗
  • Pelinck MJ, Hoek A, Simons AH, Heineman MJ, van Echten-Arends J, Arts EG. Embryo quality and impact of specific embryo characteristics on ongoing implantation in unselected embryos derived from modified natural cycle in vitro fertilization. Fertil Steril. 2010 Jul;94(2):527-34. doi: 10.1016/j.fertnstert.2009.03.076. Epub 2009 May 12. PubMed 19439287 ↗
  • Fauque P, Leandri R, Merlet F, Juillard JC, Epelboin S, Guibert J, Jouannet P, Patrat C. Pregnancy outcome and live birth after IVF and ICSI according to embryo quality. J Assist Reprod Genet. 2007 May;24(5):159-65. doi: 10.1007/s10815-007-9115-z. Epub 2007 Mar 6. PubMed 17340190 ↗
  • Ramadan WM, Kashir J, Jones C, Coward K. Oocyte activation and phospholipase C zeta (PLCzeta): diagnostic and therapeutic implications for assisted reproductive technology. Cell Commun Signal. 2012 Jul 9;10(1):12. doi: 10.1186/1478-811X-10-12. PubMed 22591604 ↗
  • Kashir J, Heindryckx B, Jones C, De Sutter P, Parrington J, Coward K. Oocyte activation, phospholipase C zeta and human infertility. Hum Reprod Update. 2010 Nov-Dec;16(6):690-703. doi: 10.1093/humupd/dmq018. Epub 2010 Jun 23. PubMed 20573804 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Aug 2027, 12 months after the start.

Of 40 observational studies under Infertility, Male, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 129. This study's planned 12 months is below that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: start Jul 2026 → Aug 2026, primary completion Jul 2027 → Aug 2027 and completion Aug 2027 → Sep 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 29, 2026
First posted
Jul 6, 2026
StartActual
Aug 1, 2026was Jul 2026
Primary completionEst.
Aug 1, 2027was Jul 2027
CompletionEst.
Sep 1, 2027was Aug 2027
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
Khalifa University is now Recruiting
Nov 12, 2026
Start date
Jul 1, 2026→Aug 1, 2026 (actual)
Nov 12, 2026
Primary completion
Jul 1, 2027→Aug 1, 2027
Nov 12, 2026
Study completion
Aug 2027→Sep 1, 2027
Nov 12, 2026
Site contacts
Changed at 2 sites. See the sites
Show 2 sites
  • Fakih IVF · Abu Dhabi, United Arab EmiratesContact removed (no phone or email listed)Contact removed (no phone or email listed)
  • Khalifa University · Abu Dhabi, United Arab EmiratesContact added j•••@ku.ac.ae · •••7302
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Khalifa University is now Recruiting
    Start date Jul 1, 2026→Aug 1, 2026 (now actual)
    Primary completion Jul 1, 2027→Aug 1, 2027
    Study completion Aug 2027→Sep 1, 2027
    Site contacts Changed at 2 sites. See the sites
    Show 2 sites
    • Fakih IVF · Abu Dhabi, United Arab EmiratesContact removed (no phone or email listed)Contact removed (no phone or email listed)
    • Khalifa University · Abu Dhabi, United Arab EmiratesContact added j•••@ku.ac.ae · •••7302
    + 2 other changes: verification date and responsible party

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07684339
Lead sponsor
Fakih IVF Fertility Center
Collaborators
Khalifa University for Science and Technology
Responsible party
Sponsor
First posted
Jul 6, 2026
Start date
Aug 1, 2026
Primary completion
Aug 1, 2027 (estimated)
Completion
Sep 1, 2027 (estimated)
Last update
Nov 12, 2026

Study contacts

Dr. Lamiya Mohiyiddeen, MD, FRCOG
Contact
lamiya.mohiyiddeen@fakihivf.com
+971543676002
Fatma Bathawab, PhD
Contact
fatma.bathawab@fakihivf.com
+971585707393
Michael Fakih, MD
principal investigator · Fakih IVF Abu Dhabi
Lamiya Mohiyiddeen, MD, FRCOG
principal investigator · Fakih IVF Abu Dhabi
Yasmin Sajjad, MD, FRCOG, DOWH
principal investigator · Fakih IVF Abu Dhabi
Junaid Kashir, PhD
principal investigator · Khalifa University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion